These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 33930312)
1. Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. Klein O; Kee D; Markman B; Carlino MS; Underhill C; Palmer J; Power D; Cebon J; Behren A Cancer Cell; 2021 May; 39(5):592-593. PubMed ID: 33930312 [No Abstract] [Full Text] [Related]
2. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386 [TBL] [Abstract][Full Text] [Related]
3. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer]. Fu MJ; Zhou JY Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877 [TBL] [Abstract][Full Text] [Related]
4. Emerging biomarkers for immune checkpoint inhibition in lung cancer. Cyriac G; Gandhi L Semin Cancer Biol; 2018 Oct; 52(Pt 2):269-277. PubMed ID: 29782924 [TBL] [Abstract][Full Text] [Related]
5. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer]. Wang S; Li J Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599 [TBL] [Abstract][Full Text] [Related]
6. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K Front Immunol; 2021; 12():646874. PubMed ID: 33927719 [TBL] [Abstract][Full Text] [Related]
7. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Garon EB Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470 [TBL] [Abstract][Full Text] [Related]
8. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. Moon EK; Langer CJ; Albelda SM Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923 [TBL] [Abstract][Full Text] [Related]
10. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs? Attili I; Passaro A; Pavan A; Conte P; De Marinis F; Bonanno L Crit Rev Oncol Hematol; 2017 Nov; 119():30-39. PubMed ID: 29065983 [TBL] [Abstract][Full Text] [Related]
11. The next generation of immunotherapy: keeping lung cancer in check. Somasundaram A; Burns TF J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399 [TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
13. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy]. Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic vaccines explored in patients with non-small cell lung cancer. Ma K; Tang YH Anticancer Agents Med Chem; 2014 Feb; 14(2):256-64. PubMed ID: 24237217 [TBL] [Abstract][Full Text] [Related]
15. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Tanvetyanon T; Gray JE; Antonia SJ Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556 [TBL] [Abstract][Full Text] [Related]
16. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly. Sgambato A; Casaluce F; Gridelli C Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698 [TBL] [Abstract][Full Text] [Related]
17. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196 [TBL] [Abstract][Full Text] [Related]
18. [Advances of the Correlation between Driver Gene Status and Immunotherapy in Non-small Cell Lung Cancer]. Chen J; Jiang D; Huang F Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):233-238. PubMed ID: 31014442 [TBL] [Abstract][Full Text] [Related]
19. [Immune alterations in lung cancer - the new therapeutic approach]. Domagała-Kulawik J; Osińska I Pneumonol Alergol Pol; 2014; 82(3):286-99. PubMed ID: 24793154 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns. Brassart-Pasco S; Dalstein V; Brassart B; Dewolf M; Clavel C; Oudart JB Pharmacogenomics; 2020 Jul; 21(10):705-720. PubMed ID: 32567537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]